Table 1 Summary of intestinal Behçet’s disease patients with myelodysplastic syndrome associated with secondary pulmonary alveolar proteinosis
Author/year (reference) | Age/sex | MDS type | BD symptoms | Chromosomal abnormalities/HLA | Respiratory symptoms | HRCT findings (GGO pattern) | Treatment before MDS onset (duration, years) | Outcome |
|---|---|---|---|---|---|---|---|---|
Handa/2014 [8] | 49/F | RA | G, I, O, S | Trisomy 8/HLA-B51- | None | Diffuse | Cyclosporine A, Prednisolone, Sulfasalazine, TNF-inhibitor (14 years) | Dead |
Handa/2014 [8] | 33/M | RA | I, O, S | Trisomy 8/HLA-B51 - | Cough | Diffuse | Azathioprine, Prednisolone, Sulfasalazine, TNF inhibitor (5 years) | Dead |
Present case/2021 | 58/F | RA | G, I, O, S | Trisomy 8, Trisomy 9, X, i(X)(q10)/HLA-B51+ | Cough Fever | Diffuse | Colchicine, Methalazine, Prednisolone, TNF inhibitor (3 years) | alive |